Atrial fibrillation burden and the risk of stroke: A systematic review and dose-response meta-analysis

INTRODUCTION

This meta-analysis demonstrated that AF burden is a significant risk factor for clinical AF and stroke. There is a linear dose-response between AF burden and risk of stroke.Further studies are needed to validate this effect and evaluate the cut-off value for AF burden among patients requiring anticoagulation treatment.

Some studies demonstrated an association between AF burden and stroke risk, but few mentioned the existence of a dose-response effect. The Italian AT 500 registry study showed that patients with device-detected AF episodes of > 24 h had a 3.1-fold increased risk of stroke. In contrast, patients with AF episodes of > 5 min and < 24 h experience no significant increase in stroke risk[7]. Moreover, the ASSERT Clinical Trial reported episodes lasting > 6 min were associated with an increased risk of ischemic stroke or systemic embolism[8]. A recent systematic review demonstrated the AF burden exceeding different thresholds was associated with an increased risk of stroke; however, they did not provide a definite threshold for AF burden at stroke risk[9]. It is a matter of controversy whether an AF burden of > 5 min can increase the risk of stroke, and no studies have reported the potential dose-response effect on stroke.Accordingly, we performed a systematic review and meta-analysis to determine the association between AF burden > 5 min and the increased risk of stroke and explored the dose-response effect between these two factors.

MATERIALS AND METHODS

This systematic review and meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines[10].

Search strategy

The literature search was performed by two researchers (YSY and HM) with the help of an experienced medical reference librarian. Studies were retrieved by searching electronic databases (PubMed, EMBASE, Medline, Cochrane, Web of Science) from inception until February 28, 2020. The following search terms were used: AF,physiological monitoring, implantable cardiac monitor, artificial pacemaker, electrocardiograph, burden, stroke, cerebrovascular disorders, brain infarction and thromboembolic event. The language of publication was restricted to English. We also retrieved the reference lists of included articles and previous reviews to identify potential studies as comprehensively as possible. All retrieved references were exported to EndNote X9, and duplicate citations were removed.

理想人格的典范和目標(biāo)深刻地影響著當(dāng)代中國人的人格建構(gòu)［6］。十八大報(bào)告提出的社會主義核心價(jià)值觀中，也十分深刻地體現(xiàn)出在繼承和發(fā)揚(yáng)優(yōu)秀傳統(tǒng)文化的基礎(chǔ)上，對當(dāng)代大學(xué)生人格發(fā)展的要求?；谏鲜鰝鹘y(tǒng)文化中理想人格的特征，大學(xué)生人格培育需要在吸取中國傳統(tǒng)文化的精華中彰顯時(shí)代發(fā)展的特質(zhì)，符合相應(yīng)的人格修養(yǎng)標(biāo)準(zhǔn)。

Inclusion criteria and exclusion criteria

Two investigators (YSY, HM) independently assessed the eligibility of the studies identified. The inclusion criteria included: (1) Studies that described AF burden within 1 d or more; (2) Studies that described the method used to quantify AF burden such as a pacemaker, implantable cardioverter-defibrillator and cardiac-resynchronization device; and (3) Studies where clinical outcomes included stroke, ischemic stroke,systematic embolism, transient ischemic attack or other thromboembolic events. The combined endpoint of these outcomes was also included: (1) Studies that directly and/or indirectly provided the relative risk of the outcome, including hazard ratio(HR), risk ratio (RR) and odds ratio (OR) values; (2) Observational studies or randomized controlled trials (RCTs); and (3) Studies where the study design and methods were described in detail.

However, reviews, conference abstracts, editorials, case reports, duplicate publications and cross-sectional studies were excluded.

Data extraction

Two researchers (YSY and HM) independently extracted the following information from the included studies: Study type, significant AF burden definition, adverse outcomes, sample size, follow-up period, the method for AF monitoring and others.The number of cases and HR, RR, OR for the risk of the adverse outcomes for different AF burdens were also recorded. HRs provided by original studies were considered as adjusted RRs. We also contacted the authors for additional data or any clarification if necessary. Disagreements were resolved by a consensus-based discussion.

Quality assessment and the level of evidence

The quantitative assessment tool ‘QualSyst’[11] and the Oxford Centre for Evidence-Based Medicine 2009 Level of Evidence Tool[12] were used to assess the methodological quality and the evidence levels of the included studies by two researchers (YSY and HMJ). The ‘QualSyst’ scoring system included 14 criteria with three possible answers: Yes, No, and Partial. “Yes” = 2 points, “No” = 0 points and “Partial” = 1 points. Items not applicable to a particular study design were marked ‘NA’ and were excluded from calculating the summary score. A summary score was calculated for each article based on the evaluation criteria. A score greater than 75% of the summary score indicated strong quality, a score ranging from 55% to 75% indicated moderate quality, and a score lower than 55% indicated poor quality. The level of evidence was assessed according to the type of study, and each subgroup level included five levels.

Data synthesis and statistical analysis

Grade A (Excellent): 0

AF burden > 5 min was associated with an increased risk of clinical AF [adjusted risk ratio (RR) = 4.18, 95% confidence interval (CI): 2.26-7.74]. However, no association was found with an increased risk of all-cause mortality (adjusted RR =1.55, 95%CI: 0.87-2.75). Patients with AF burden > 5 min had an increased risk of stroke (adjusted RR = 2.49, 95%CI: 1.79-3.47). Moreover, a dose-response analysis showed that the increased stroke risk was paralleled by an increase in AF burden at a rate of 2.0%hour (= 0.656, RR = 1.02, 95%CI: 1.01-1.03). Trial sequential analysis provided robust evidence of the association between AF burden > 5 min and an increased risk of stroke.

Moreover, when the AF burden was not a definite value, the midpoint between the upper and lower boundaries was considered as the average AF burden; when the lowest level was an open interval, the lowest dose was assumed to be 0; when the highest category was open-ended, a value with 1.5 times of the boundary of the highest dose was considered the dose[16]. Trial sequential analysis (TSA) was used to evaluate the statistical power of the current sample size and provide robust evidence of the effect of AF burden on the stroke risk[17]. Heterogeneity-adjusted required information size was calculated with α = 0.05, β = 0.2 and a relative risk reduction of 30%.

The meta-analysis was conducted using Review Manager (v5.3). The potential doseresponse association was conducted by STATA software (v15.0, College Station, TX,United States). TSA was conducted with TSA 0.9.5.10 Beta software (http://www.ctu.dk.tsa)[18].

RESULTS

Identification of studies

The search strategy yielded a total of 10479 abstracts from five English databases,while a manual search of the references cited in other available included articles and previous reviews yielded an additional 372 abstracts. After removing duplicates, 7827 studies remained. After abstract screening, 7004 studies were excluded. The remaining 823 full-texts were assessed for eligibility based on the inclusion and exclusion criteria,and 807 studies were excluded for the following reasons: 412 were not original articles,218 lacked detailed data on AF burden and 126 did not provide information on the clinical outcomes, 44 had a history of AF or stroke, and seven were cross-sectional studies. Finally, 16 studies were included in the quantitative synthesis (Figure 1).

Characteristics of the involved studies

Table 1 shows the characteristics of the included 16 studies, all except one were RCT studies[7,8,19-32]. The detected devices for AF burden included one or more of the three following devices: Pacemaker, implantable cardioverter-defibrillator and cardiac-resynchronization device. The 16 studies included 53141 subjects with mean or median ages > 65 years. Except for case-crossover study, subjects in all studies were followed up for at least 1 year to ascertain the clinical outcomes[25]. Four studies were multinational consortium studies; six were conducted in European countries, four in North American countries and two in Asian countries.

僅就融資功能而言，中國金融業(yè)一方面尚未建立覆蓋一、二、三產(chǎn)業(yè)及不同所有制企業(yè)的服務(wù)體系。此外，因資本市場的長期萎靡不振而使中國的融資體系一直表現(xiàn)得過度偏狹，同時(shí)對技術(shù)研發(fā)創(chuàng)新的融資現(xiàn)尚處摸索階段；人們在不同地域多元配置資產(chǎn)的愿望也未能得到滿足，金融機(jī)構(gòu)自身也主要依靠傳統(tǒng)方式去消化自身的經(jīng)營風(fēng)險(xiǎn)。這就是金融業(yè)跟不上社會經(jīng)濟(jì)發(fā)展的問題。

Table 2 shows the quality evaluation and the evidence level for each study. Twelve studies were associated with scores higher than 21. The levels of evidence ranged from 1b to 3a, and most were considered level 2b evidence.

為進(jìn)行軍民融合，雙方作出妥協(xié)和改動是不可避免的，而融合標(biāo)準(zhǔn)制定的一個(gè)重要原則就是在標(biāo)準(zhǔn)層面上就應(yīng)考慮融合會帶來的影響，并在標(biāo)準(zhǔn)融合時(shí)將這種影響降到最低。

The incidence of AF burden > 5 min and stroke

Eleven studies provided data on the incidence of AF burden > 5 min. The detectable rate of AF burden > 5 min ranged from 10.12% to 70.77% among CIED patients, and AF burden > 24 h ranged from 6.70% to 39.26%. Overall, AF burdens > 5 min and > 24 h were detected in 26% (95%CI: 1%-52%) and 15% (95%CI: 6%-35%) of patients within the follow-up period, respectively, and the pooled incidence of stroke was 2.80%(95%CI: 1.56%-4.03%).

Association between AF burden > 5 min and future stroke risks

Sufficient data were obtained to calculate the crude RR for stroke associated with AF burden > 5 min in each study. The average follow-up for the 11 studies ranged from 12 to 67 mo (mean = 36.18 mo). The random-effects pooled analysis revealed that patients with AF burden > 5 min had a 67% increased risk of stroke (RR = 1.67, 95%CI: 1.25-2.25) compared with patients with AF burden < 5min (Figure 2A). Significant heterogeneity was found within the included studies (= 52%,= 0.020). The funnel plot was symmetrical, and Egger’s test showed no significant publication bias (= 1.56,=0.150).

TSA of ten studies showed that 71.5% (37144 out of 51978 patients) of the heterogeneity-adjusted information size required was accrued. We also found that the 1.08,= 0.340) among these studies.cumulative Z curve crossed the trial sequential monitoring boundary, providing robust evidence of the association between the AF burden > 5 min and increased risk of stroke based on the sample size (Figure 3).

Subgroup analyses of association between AF burden > 5 min and the future stroke risk

The fixed-effect pooled analysis performed with adjusted RRs revealed that patients with AF burden > 5 min had a 1.23-fold increase in risk of stroke (RR = 2.23, 95%CI:1.48-3.35), compared to AF burden < 5 min among patients with no history of AF.Moreover, patients with AF burden > 5 min had a 2.14-fold increase in the risk of stroke (adjusted RR = 2.14, 95%CI: 1.23-3.72) compared to AF burden < 5 min among patients not on anticoagulation therapy. The detailed results of subgroup analyseswith different populations are shown in Supplementary Table 1.

Does-response relationship between AF burden and the future stroke risk

Seven studies were included in the dose-response meta-analysis on the association between AF burden and stroke. The potential linear or nonlinear dose-response association was evaluated using a restricted cubic splines regression model. A linear dose-response relationship(= 0.656) was found (Figure 4),and AF burden was associated with 2.0% and3.0% increased risksofstroke for every 1h (RR =1.02,95%CI: 1.01-1.03) and 2 h (RR = 1.03, 95%CI: 1.02-1.05), respectively.

AF burden and risk of clinical AF

Three of the included studies, including 3286 patients, provided adjusted RRs values of the AF burden > 5 min on the risk of clinical AF. The random-effect pooled analysis reveal that patients with AF burden > 5 min had a 3.18 fold increased risk of clinical AF (adjusted RR = 4.18, 95%CI: 2.26-7.74) compared with the patient suffering AF burden < 5 min (Figure 5). The heterogeneity was significant among the different study designs (= 77%,= 0.010), RCT[19] and two retrospective observational studies[8,26]. The funnel plot was symmetrical and no significant publication bias was found in the Egger’s test (= 0.80,= 0.570).

AF burden and the risk of all-cause mortality

The reported adjusted RRs for the strength of association between AF burden > 5 min and risk of all-cause mortality in three studies differed. An ancillary study of the Mode Selection Trial trial[19] included patients with sinus node disease who were in sinus rhythm at the time of pacemaker implantation and aged > 21 years. Two studies[23,26]included patients with no history of AF. The random-effects pooled analysis found that patients with AF burden > 5 min had a 55% increased risk of all-cause mortality(adjusted RR = 1.55, 95%CI: 0.87-2.75) (Figure 6); however, significant heterogeneity (= 68%,= 0.040) and publication bias (= -21.13,= 0.030) were present in this analysis.

供給情況：國產(chǎn)鉀方面，鹽湖裝置正常運(yùn)作，日產(chǎn)1.4萬噸，日發(fā)運(yùn)200-300車，青海小廠開工率維持低位；青海鹽湖庫存略降，基準(zhǔn)產(chǎn)品60%晶粉到站價(jià)維持2350元/噸，各地經(jīng)銷商到站參考報(bào)價(jià)維持2200元/噸。進(jìn)口鉀方面，到船量仍較少，港口鉀庫存180萬噸，市場可售現(xiàn)貨緊俏；貿(mào)易商看漲預(yù)期仍強(qiáng)，62%俄白鉀主流報(bào)價(jià)維持2350元/噸。邊貿(mào)鉀方面，到貨量較少，庫存偏低，貨源供應(yīng)持續(xù)偏緊，62%俄白鉀報(bào)價(jià)漲至2150元/噸。

DISCUSSION

In this systematic review and dose-response meta-analysis on the association between AF burden and the risk of stroke, 16 original studies were included, including 53141 CIED patients. First of all, we found that patients with an AF burden > 5 min had an increased risk of stroke. Moreover, a linear dose-response relationship was found; the risk of stroke was increased by 2.0%hour among subjects with AF burden > 5 min.Last but not least, we found AF burden > 5 min was associated with a significantly increased risk of clinical AF but not associated with an increase in all-cause mortality.

AF burden: A significant risk factor for stroke

Data from each study were extracted to calculate the crude RRs without considering the time-to-event endpoints. The pooled results indicated that patients with AF burden> 5 min had a higher stroke risk. That significant heterogeneity was detected for the pooled analysis of the relationship between AF burden and stroke risk (= 52%,=0.02). The heterogeneity might be associated with the variations in patient populations,hypertension, prior AF and antithrombotic therapy,.[33]. The population included in our study had different comorbidities, including patients with symptomatic atrial tachyarrhythmias[7,20], sinus node disease[19] and heart failure[22]. Moreover, some studies provided no information on patient history of AF[8,23,26-28]. Besides, in the study by Chu[29], patients with oral anticoagulants for any reason were excluded.However, even though anticoagulants were used in different proportions of patients at baseline, we found that the heterogeneity was not significant. With the pooled data of HRs adjusted for one or more known embolism predictors [including age, sex, heart failure, prior stroke diabetes, congestive heart failure, hypertension, age 75 years,diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, sex category (CHA2DS2-VASc) score], we found that an AF burden > 5 min was associated with an increased risk of stroke (= 0,= 0.62).

We found that subjects with AF burden of > 5 min had a 67% increased risk of stroke. Recently, a meta-analysis also found that subclinical AF (pooled with highest AF duration cut-off values from the original studies) was associated with a 2.4-fold increased risk of stroke[9]. These results indicated that the risk of stroke was higher among the subjects with the serious AF burden. This finding provides novel insights that can be used to develop stroke prophylaxis approaches for AF patients.

Consistently, Shanmugam[22] found that a higher AF burden (AF burden > 3.8 h) was associated with a 9.4-fold risk of stroke among CIED patients. Two studies[28,30] also reported that patients with AF burden > 24 h had an increased risk of stroke.However, these results were inconsistent with a study by Healey[8], which could be accounted for by the fact that patients who experienced long periods of sinus rhythm and the better treatment of stroke had no history of AF[8].

The European and American[34] guidelines recommend estimating stroke risk in AF patients based on the CHA2DS2-VASc score. Moreover, an oral anticoagulant is recommended to reduce thromboembolic stroke risk in patients with AF, especially male patients with a CHA2DS2-VASc score of 1 and female patients with a CHA2DS2-VASc score of 2. Interestingly, some studies explored the association between AF burden and CHA2DS2-VASc scores. Botto[20] indicated that patients with a CHADS2 score of 1 or 2 had either a high or low stroke risk consistent with a high or low detected AF duration, respectively. Kaplan[30] also found an interaction between AF duration and CHA2DS2-VASc score. The risk of systemic embolism in patients with intermediate CHA2DS2-VASc scores was variable and correlated with the maximum AF burden. Accordingly, the stroke risk among AF patients should be evaluated based on the CHA2DS2-VASc score and AF burden to provide better personalized anticoagulation decisions.

Association between AF burden and risk of clinical AF or all-cause mortality

Clinical AF is a chaotic heart rhythm characterized by an irregular and often rapid heart rate documented with a 12-lead electrocardiogram. Electrocardiogramdocumented AF was confirmed in 38.9% of patients with AF burden and 2.1% without AF burden[19]. Our study found that AF burden > 5 min was associated with an increased risk of clinical AF. Furthermore, progression from paroxysmal to persistent or permanent AF might be faster in patients with subclinical AF who did not receive treatment. Consequently, more emphasis should be placed on screening patients with AF burden > 5 min and providing timely therapy.

Our study demonstrated that AF burden was not associated with all-cause mortality. However, there was significant heterogeneity in this meta-analysis. Indeed,further research is required to explore the role of AF burden on all-cause mortality.

Limitations

Even though this meta-analysis was performed utilizing crude RRs and adjusted RRs,there are still some limitations. Owing to the lack of adjusted RRs corresponding to three or more groups of AF burden, this meta-analysis was conducted without considering the time-to-event points and adjusting for confounding factors.Furthermore, patients with CIEDs might have diabetes, hypertension and other stroke risk factors, which might lead to an overestimation of the effect of AF on stroke.Underreporting of stroke and prescribing an oral anticoagulant to patients with higher AF burden might also lead to underestimating the impact of AF burden on the stroke risk. However, anticoagulation was used in the different subgroups of patients who had comorbidities at the baseline. Finally, publication bias was present in this study.Our results might have been influenced by non-published studies or language bias as we only included studies published in English.

黃國滋等[22]對普洱茶曬青毛茶和陳香茶中可溶性糖在儲存過程中的變化進(jìn)行研究，在3種不同的儲存環(huán)境下儲存540 d，2類茶可溶性糖的保留量與儲存時(shí)間成反比，即隨著儲存時(shí)間的延長，其可溶性糖的保留量逐漸減少。

CONCLUSION

Atrial fibrillation (AF) is one of the most frequent cardiac arrhythmias. Reports suggest that an estimated 12.1 million people will suffer from this condition in the United States by 2030 and 17.9 million people in Europe by 2060[1,2]. It has been established that patients with AF have a 3 to 5-fold increased risk of stroke, and subjects with AF-related embolic stroke have a worse progression than those who experience stroke not related to AF[3-5]. With the widespread use of cardiac implantable electronic devices (CIEDs) and wearable devices, it is now possible to monitor the time and frequency of AF episodes. The American Heart Association recommends that the AF burden should be defined as the duration of the longest AF episode during a defined monitoring period[6].

利用研制的晶體管直流增益在線測試系統(tǒng)，以BCX41和3CK3B兩種晶體管器件作為試驗(yàn)樣品，在CFBR-II堆上開展了不同中子輻照注量效應(yīng)試驗(yàn)，分別獲得了輻照功率為2，20，200 W下晶體管的直流增益變化趨勢，結(jié)果如圖8—圖10所示。

AF burden is a significant risk factor for clinical AF and stroke. A significant linear association is present between increased AF burden and the risk of stroke.

More emphasis should be laid on patients with AF burden to minimize the stroke risks.

ACKNOWLEDGEMENTS

We are grateful to Meng-Jiao He and Fei-Hong Chen for their helpful advice of methodology and statistics and to Mr. Satyajit Kundu for language polishing.